The Gates Biomanufacturing Facility
Chemicals & Related Products · Colorado, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
12635 E Montview Blvd Ste 380, Aurora, C...Phone Number
(303) 724-1274Revenue
$5.6 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
2
1
1
1
1
About The Gates Biomanufacturing Facility
Gates Biomanufacturing Facility is an academic Good Manufacturing Practice (GMP) facility that specializes in the development and manufacture of groundbreaking cellular, gene-modified, and protein biologic therapies. The facility collaborates with biomedical researchers and biotechnology companies to efficiently translate new agents into Phase I clinical trials. With a focus on patient care, GBF aims to move scientific discoveries from bench to bedside, ensuring high-quality manufacturing of Advanced Therapy Medicinal Products. Located in Aurora, Colorado, it benefits from close ties with local hospitals and clinics, enhancing its capabilities in the medical ecosystem.Explore more
The Gates Biomanufacturing Facility Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is The Gates Biomanufacturing Facility your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at The Gates Biomanufacturing Facility
Click to see if The Gates Biomanufacturing Facility had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if The Gates Biomanufacturing Facility has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on The Gates Biomanufacturing Facility recently announced quarterly report
Check out if The Gates Biomanufacturing Facility is spiking on competitors!
Product Launch: Get notified when The Gates Biomanufacturing Facility launches new products
Funding: Get notified immidiatlly once The Gates Biomanufacturing Facility has new funding data
The Gates Biomanufacturing Facility, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Reach out to Masked Content who joined The Gates Biomanufacturing Facility as Masked Content
Find 3 more new buyers
Compare Similar Companies to The Gates Biomanufacturing Facility
Compare insights from companies similar to The Gates Biomanufacturing Facility, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
The Gates Biomanufacturing Facility is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
The Gates Biomanufacturing Facility is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about The Gates Biomanufacturing Facility.
The Gates Biomanufacturing Facility Tech Stack
A closer look at the technologies used by The Gates Biomanufacturing Facility
See more technologies
The Gates Biomanufacturing Facility News & Media
Read more news
Top Chemicals & Related Products Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding The Gates Biomanufacturing Facility
Sign Up For FreeTo access detailed company insights
Gates Biomanufacturing Facility is an academic Good Manufacturing Practice (GMP) facility that specializes in the development and manufacture of groundbreaking cellular, gene-modified, and protein biologic therapies. The facility collaborates with biomedical researchers and biotechnology companies to efficiently translate new agents into Phase I cl... Read More
